References
- Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatients Study Investigators. N Engl J Med 1998; 338: 853–60.
- Carpenter CCJ, Cooper DA, Fishl MA, et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society—USA Panel. JAMA 2000; 283 (3): 381–90.
- Roberts KJ. Barriers to and facilitators of HIV-positive patients' adherence to antiretroviral treatment regimens. AIDS Patients' Care STD 2000; 14 (3): 155–68.
- Chesney MA, Morin M, Sherr L. Adherence to HIV combination therapy. Soc Sci Med 2000; 50: 1599–605.
- Metha S, Moore RD, Graham NMH. Potential factors affecting adherence with HIV therapy. AIDS 1997; 11: 1665–70.
- Miller NH. Compliance with treatment regimens in chronic asymptomatic disease. Am J Med 1997; 17: 43–9.
- Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14: 357–66.
- Viracept (Rm) (nelfinavir mesylate). Prescribing informa-tion. Auguron Pharmaceuticals, Inc.; La Jolla, CA, USA; 1999 Nov 24.
- Gatell J. and the AVANTI study group. AVANTI 3. A randomised, double blind, comparative trial to evaluate the efficacy, safety and tolerance of AZT/3TC vs AZT/3TC/nelfi-navir in antiretroviral naïve patients: 52 weeks data 4th International Congress on Drug Therapy in HIV Infection 1998 Nov 8-12 Glasgow.
- Petersen A, Antunes F, Arasteh KN, et al. Comparison of the long-term antiviral efficacy of BID and TID dosing of nelfinavir in combination with stavudine (d4T) and lamivudine (3TC) beyond 48 weeks. 7th European Conference on Clinical Aspects and Treatment of HIV infection; Lisbon 23-27 October 1999, abstr.
- Palella F, Gathe J, Brutus A, et al. Long term response among patients receiving nelfinavir (NFV) and dual NRTIs as first ever HAART (Abstract 227). 1st IAS conference on HIV pathogenesis and treatment, July 8-11, 2001- Buenos Aires, Argentina.
- Gathe J, Chu A, Yuen N, et al. Durability of nelfinavir combination therapy after 4 years: 3 years' extension data from Agouron study 511 (LB/P 10). 8th European Conference on Clinical Aspect and Treatment of HIV Infec-tion, Athens, 28-31 October 2001.
- Kravcik S, Magill A, Sanghvi B, et al. Comparative CD4 T-cell responses of reverse transcriptase inhibitor therapy with or without nelfinavir matched for viral exposure. HIV Clin Trials 2001; 2 (2): 160–70.
- Barreiro P, Oiler V, Soriano V, Nunez M, Rodriguez-Rosado R, Gonzalez-Lahoz J. Performance of a quadruple combination including nelfinavir plus efavirenz in naive sub-jects with high baseline viral load and in patients failing pro-tease inhibitor-containing regimens. J AIDS 2001; 26 (4): 391–2.